/rss/search.php?qu=/rss/search.php?qu=/rss/search.php?qu= RSS Page 8

Filtered By:
Cancer: Prostate Cancer

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 25217 results found since Jan 2013.

MicroRNAs Regulate Tumorigenesis by Downregulating SOCS3 Expression: An < em > In silico < /em > Approach
This study identifies the interactions of known (miR-203a-5p) and novel (miR-6756-5p, miR-6732-5p, miR-1203, miR-6887-5p) microRNAs with SOCS3 regions due to their maximum interactions. Identifying the interactions of these microRNAs with SOCS3 will significantly advance the understanding of oncomiRs (miRNAs that are associated with cancer development) in tumor development due to their influence on SOCS3 expression. These insights will assist in future studies to understand the significance of miRNA-SOCS3-associated tumor development and progression.PMID:37701630 | PMC:PMC10493049 | DOI:10.1177/11779322231193535
Source: Bioinformatics and Biology Insights - September 13, 2023 Category: Bioinformatics Authors: Sura Al-Asadi Hiba Mansour Ahmed Jwaid Ataimish Rusul Al-Kahachi Jamila Rampurawala Source Type: research

Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer
Urologie. 2023 Sep 13. doi: 10.1007/s00120-023-02189-z. Online ahead of print.ABSTRACTProstate-specific membrane antigen (PSMA) hybrid imaging is a promising new technique gaining importance in the field of prostate cancer (PCa) diagnosis and treatment planning. By combining PSMA radioligands and computed tomography (CT) or magnetic resonance imaging (MRI), PSMA hybrid imaging opens up new diagnostic opportunities. PSMA-PET/CT (PET: positron-emission tomography) is already well established in high-risk PCa for primary staging and tumor localization when biochemical recurrence occurs. Further potential indications for PSMA-...
Source: Nuklearmedizin - September 13, 2023 Category: Radiology Authors: Anna-Sophie Strau ß Christian Bolenz Ambros J Beer Friedemann Zengerling Meinrad Beer Jonathan Miksch Source Type: research

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders
CONCLUSIONS: Regional differences in mutations may exist with advanced stage accounting for prevalence of specific mutations. A national Trial Finder shows utility in finding targeted trials whilst commercial sequencing reports may over-report 'actionable' mutations. Understanding local prevalence and trial availability could increase enrolment onto matched early phase trials.PMID:37702806 | DOI:10.1007/s00432-023-05365-y
Source: Clinical Colorectal Cancer - September 13, 2023 Category: Cancer & Oncology Authors: S Rae E Plummer L Fitzgerald L Hogarth A Bridgewood L Brown-Schofield J Graham S Haigh C McAnulty Y Drew N Haris S Bashir R Plummer A Greystoke Source Type: research

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders
CONCLUSIONS: Regional differences in mutations may exist with advanced stage accounting for prevalence of specific mutations. A national Trial Finder shows utility in finding targeted trials whilst commercial sequencing reports may over-report 'actionable' mutations. Understanding local prevalence and trial availability could increase enrolment onto matched early phase trials.PMID:37702806 | DOI:10.1007/s00432-023-05365-y
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: S Rae E Plummer L Fitzgerald L Hogarth A Bridgewood L Brown-Schofield J Graham S Haigh C McAnulty Y Drew N Haris S Bashir R Plummer A Greystoke Source Type: research

Fibroblast Activation Protein-Targeted PET/CT Imaging in a Treatment-Naive Prostate Cancer Patient With Low PSMA Expression
Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004825. Online ahead of print.ABSTRACTProstate-specific membrane antigen (PSMA) PET/CT has become increasingly accepted for imaging prostate cancer (PCa), including its recent use in primary staging. In this case report, we present the case of a 76-year-old man with newly diagnosed PCa. 18F-PSMA-1007 PET/CT showed minimal PSMA activity in the primary tumor and metastases. However, 18F-FAPI-04 PET/CT revealed more avid lesions in primary tumor, metastatic lymph nodes, and bones. Subsequent histopathologic examination confirmed the diagnosis of PCa. These findings suggest...
Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Xingyu Mu Meng Li Jingquan Huang Zhenzhen Wang Wei Fu Source Type: research

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders
CONCLUSIONS: Regional differences in mutations may exist with advanced stage accounting for prevalence of specific mutations. A national Trial Finder shows utility in finding targeted trials whilst commercial sequencing reports may over-report 'actionable' mutations. Understanding local prevalence and trial availability could increase enrolment onto matched early phase trials.PMID:37702806 | DOI:10.1007/s00432-023-05365-y
Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: S Rae E Plummer L Fitzgerald L Hogarth A Bridgewood L Brown-Schofield J Graham S Haigh C McAnulty Y Drew N Haris S Bashir R Plummer A Greystoke Source Type: research

Improving diverse participation in cancer clinical trials
Trans Am Clin Climatol Assoc. 2023;133:149-156.ABSTRACTDespite significant improvement in overall cancer mortality (>30% since 1991), these survival benefits have not been experienced by all groups uniformly especially in those of diverse heritage. Drivers of cancer health inequity are multi-factorial including more adverse social determinants of health, later stage cancer presentation, decreased health care access, decreased health literacy, and cultural barriers to prompt cancer care. Adding to these disparities is the historical inclusion of primarily well-insured Caucasian patients into cancer clinical trials leadin...
Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Ruben Mesa Rebecca T Jones Source Type: research

Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer
CONCLUSION: With excellent local control and tolerance, SBRT for omHSPC patients represents an attractive approach to defer systemic therapeutic escalation and prevent its side effects. Accurate patient selection for SBRT requires more data with longer follow-up and higher numbers of patients pending the results of upcoming randomized trials.PMID:37701481 | PMC:PMC10493250 | DOI:10.1016/j.ctro.2023.100673
Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: D Baron D Pasquier T Pace-Loscos B Vandendorpe R Schiappa C Ortholan J M Hannoun-Levi Source Type: research

Immune responses of six-transmembrane epithelial antigen of the prostate 4 functions as a novel biomarker in gastric cancer
CONCLUSION: The current findings suggest an oncogenic role for STEAP4 in GC, with significantly high levels being associated with poor prognosis. Investigation of the GC tumor microenvironment suggests the potential function of STEAP4 is connected with the infiltration of diverse immune cells, which may contribute to the regulation of the tumor microenvironment. In conclusion, STEAP4 may serve as a potential therapeutic target for GC to improve the immune infiltration, as well as serve as a prognostic biomarker for judging the prognosis and immune infiltration status of GC.PMID:37700807 | PMC:PMC10494559 | DOI:10.5306/wjco.v14.i8.297
Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Ze-Xuan Fang Yan-Yu Hou Zheng Wu Bing-Xuan Wu Yu Deng Hua-Tao Wu Jing Liu Source Type: research

Development and validation of a nomogram (APGRC) to predict the presence of germline DNA damage repair pathogenic variants in Asian patients with prostate cancer
Clin Transl Med. 2023 Sep;13(9):e1411. doi: 10.1002/ctm2.1411.NO ABSTRACTPMID:37700486 | PMC:PMC10497832 | DOI:10.1002/ctm2.1411
Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Tingwei Zhang Yu Wei Boon Hao Hong Takayuki Sumiyoshi Enya Hui Wen Ong Hao Zeng Yonghong Li Chi-Fai Ng Jian Pan Bangwei Fang Beihe Wang Junlong Wu Hongkai Wang Shusuke Akamatsu Melvin Lee Kiang Chua Dingwei Ye Yao Zhu Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20